Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Analisten , rapporten etc
Volgen
Uit andere degelijke bron (geeft in 'Jip & Janneke taal' weer waar het over gaat)What happened: • ProQR released positive interim results from its Phase 1/2 trial of QR-110 for Leber congenital amaurosis type 10 (LCA10). While the trial was not powered for any statistical significance, QR-110 demonstrated a remarkable improvement in vision for the majority of subjects such that these results have prompted ProQR to announce its intent to start a Phase 2/3 pivotal trial in 1H19 despite only having results from 10 patients dosed at relatively low doses for 3 months. • The ongoing Phase 1/2 trial is a safety and proof of concept trial, with multiple exploratory efficacy outcomes. Though the minimum treatment period is 12 months, ProQR moved up the interim analysis to 3 months due to positive emerging data from just the first two dose cohorts. 62.5% (5 of 8) of patients showed improvement in best corrected visual acuity (BCVA) (improvement of greater than -0.3 LogMAR from baseline) and in the ability to navigate a customized mobility course. There was a meaningful improvement in full field stimulus test (FST) and nystagmus tracking (ocular instability; OCI). • At this point in the trial, QR-110 has proven to be safe and well-tolerated, with no serious adverse events (SAEs) related to the treatment or injection procedure. There were some mild local adverse events at the injection site, but there was no evidence of inflammation and no patients have discontinued treatment early. Our take: • BCVA as measured by logarithm of the minimum angle of resolution (logMAR) is the most important registrational endpoint for ophthalmic therapies, with the traditional clinically meaningful threshold being -0.3 logMAR (3 lines on an eye chart). At interim analysis, patients experienced an improvement of -0.67 logMAR in their treated eye versus 0.02 logMAR in their untreated eye. Though the sample size was small (n=8) and the trial was not powered for statistical significance, the improvement in mean logMAR was nevertheless statistically significant (p=0.011). • The data included results from 3 pediatric patients and 5 adults. There was a clear correlation between baseline visual acuity and likelihood to respond to therapy, and the two non-responders were adults that started with very low baseline visual acuity. ProQR has not confirmed what patient population will be used for the pivotal trial, but since younger patients are more likely to be significant responders, we expect to see this reflected in the enrollment of the Phase 2/3 trial. • ProQR’s drug candidates are unified by the fact that they are all RNA-based molecules that exert their effects on mutated mRNA such that a wild-type or at least functionally correct protein can be made from the corrected mRNA. ProQR’s drugs have either been shown clinically, or are expected, to have a highly favorable safety profile. ProQR circumvents the historical problem of RNA-based drugs being difficult to usefully give systemically by focusing solely on diseases that can be addressed with local drug administration. This is exemplified by ProQR’s focus on ophthalmic diseases that can be treated with injections directly into the eye, which delivers the drug to the target area and minimizes the chances for systemic toxicity. We believe that today’s results will further increase ProQR’s focus on its ophthalmic franchise.
PROQR THERAPEUTICS N.V. PRQR | $21.60 OUTPERFORM | TARGET PRICE: $35.00 Initiating Coverage Josh Schimmer 310-473-2942josh.schimmer@evercoreisi.com Maneka Mirchandaney 212-497-0881maneka.mirchandaney@evercoreisi.com Shenstone Huang 212-446-9436shenstone.huang@evercoreisi.com Amy Liu 212-497-0825amy.liu@evercoreisi.com Initiating Coverage At Outperform With $35PT And At Last I See The Light We are initiating coverage on PRQR with an OP rating and $35 price target. The company's recent clinical data for QR-110 for treatment of LCA-10 (congenital cause of blindness) has transformed the outlook for the company. The striking results not only appear to establish proof of concept for the lead program, it also helps de-risk the company's broader platform. ¦ A whole new PRQR world: Some still associate PRQR with its initial mRNA targeting program for cystic fibrosis, which has failed to resonate with the investor community. But the company has steadily re-positioned its platform to focus on other topical indications such as ophthalmology and dermatology. With QR-110 off to the races and validating its strategy, we can turn our attention to the rest of its pipeline. ¦ Eye to eye: Clinical data for QR-110 far surpassed our expectations with a number of LCA-10 patients experiencing dramatic improvements in vision. Given ONCE's Luxturna's ability to navigate development/regulatory hurdles to reach commercialization for LCARPE65, we believe the trail has been blazed for QR-110 to advance rapidly to market. The price of '110 will depend on whether or not the rest of the pipeline bears fruit, so we believe peak (2024) sales could range from $150-$225M. As such, this program alone could justify upside to the current valuation (assuming 4-5x peak revenue). ¦ More to potentially come: QR-110 validated mRNA targeting therapeutics for retina diseases, and so did Vitravene back in the day for CMV retinitis. Other RNAi/ASO companies have pursued target organs like liver and CNS, leaving PRQR a niche in eye and skin, where local delivery obviates need for systemic exposure/ risks. Watch for clinical results from QR-313 (Exon 73 skipper) for Dystrophic Epidermolysis Bullosa in 2H18 (a potential $100M+ oppy) and QR-421a (Exon 13 skipper) for Usher Syndrome in mid-2019 (potential $400M+ oppy). ¦ So much more than a dream: We are in the midst of a wave of DNA/mRNA targeting therapies. One of the most exciting aspects of these is their modularity. Once proof of concept in a target organ is established for one genetic disease, the targeting sequence can be swapped out to address another disease while keeping everything else the same. Initial success with QR-110 bodes extremely well for the rest of PRQR's locally administered pipeline-- both disclosed programs as well as undisclosed ones in even earlier pre-clinical stages. ¦ Key risks: Traditional development, regulatory, commercial (inc pricing) and competitive (from other platforms/companies inc EDIT and WVE) risks for an emerging platform in the gene targeting field apply to PRQR's portfolio. zie verder!: evercore.na.bdvision.ipreo.com/NSight...
AB ivet. Het enige wat we moeten doen is het nauwkeurig volgen van Editas en WVE , zoals aangegeven door Evercore.www.bloomberg.com/quote/WVE:US
ProQR (PRQR) Receives a Buy from H.C. Wainwrightwww.smarteranalyst.com/brief/proqr-pr...
cantor2.bluematrix.com/sellside/Email... (hier is 2e oogprogramma mee in opgenomen) ProQR Therapeutics N.V. (PRQR- $18.51) Rating: Overweight Price Target: $40.00 Usher-ing in upside with data in Usher Syndrome in 2019; Initiate at Overweight, $40 PT REV 1Q 2Q 3Q 4Q 2017A 0.0A 0.0A 0.0A 1.0A 2018E 0.0A 1.0A 3.0A 0.0E 2019E 0.0E 0.0E 0.0E 0.0E EPS 1Q 2Q 3Q 4Q 2017A (0.45)A (0.47)A (0.42)A (0.39)A 2018E (0.34)A (0.23)A (0.18)A (0.24)E 2019E (0.25)E (0.27)E (0.28)E (0.29)E FY 2017A 2018E 2019E REV 1.0A 4.4E 0.0E EPS (1.72)A (0.96)E (1.09)E REV?in?€M;?EPS?in?€/sh Investment Summary. Initiating at OW and $40 12-month PT. ProQR is a European RNA-based platform technology company focused on developing therapeutics for inherited blindness. Although shares are up close to 500% YTD (vs. XBI down 9%) after positive proof of concept in first ophthalmology drug QR-110, we think this could be just the beginning of a major turning point for the company’s platform. In September, ProQR established the first proof of concept for its RNA platform in inherited ophthalmology with lead asset QR-110. We think QR-110 could be just the tip of the iceberg in terms of PRQR’s platform potential in inherited forms of blindness. In this report, we are focused on the company’s next clinical program in Usher’s Syndrome which represents a larger opportunity than QR-110 (we estimate $1.1B peak vs. $300M peak) and is guided to have clinical data in 2019. n We think LCA10 data provided not only positive data but also gives us increased confidence in platform capability and the next drug in clinic, QR-421a. Lead asset, QR-110, is targeting an ultra-rare genetic eye disease called Leber’s congenital amaurosis type-10 (LCA10). We believe that QR-110's proof-of-concept study provided compelling evidence of efficacy and we estimate peak sales of $300M. Almost as important as the compelling LCA10 data, we think that this proof-of-concept data gave us reason to believe that Usher’s Syndrome and other ophthalmology indications may be successful using this platform technology. Key reasons we discuss in this report: 1) same delivery, chemistry, safety and PK/PD profile as QR-110, 2) both programs target proteins in the cilia in the retina, 3) USH2A patients have more retinal cells intact than LCA10 patients. n USH2A clinical data in '19 could be a major value driver. We think it is underappreciated by investors making risk/reward attractive into the readout: Shares could trade +150-225% (to ~$47-$62) vs. -30-60% ($8-$13/sh). Mutations in the USH2A gene lead to blindness due to lack of a protein called usherin. QR-421a is an exon skipping approach that could lead to increased truncated usherin. QR-421a is moving into patients by early '19 and we expect initial data in mid to 2H2019. If QR-421a is successful, we think it could sell $1.1B+ at peak which is a nearly a ~4x larger opportunity than QR-110 ($300M). n Inherited ophthalmology diseases where PRQR’s platform is focused represent a very large opportunity. We estimate $4.5B+ in peak unadjusted sales across PRQR’s disclosed clinical and preclinical targets. ProQR will have two programs in clinical development by early '19 and is guiding for more to enter the clinic over the next 12-18 months. At ~$750M in cap, we think current levels give credit for the LCA10 opportunity, but not the platform’s potential including QR-421a which is guided to have proof of concept data in 2019. Current Statistics Market Cap ($Mil) $714 Avg. Daily Trading Volume (3 mo.) : 482,576 Shares Out (Mil) : 38.5 52 Wk. Range $24.00 - $2.75 The Disclosure Section may be found on pages 96 - 99.
See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures. Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Certain products (not inconsistent with the author's published research) are available only on Citi's portals. 15 Nov 2018 00:05:00 ET ¦ 49 pages Biotechnology North America ¦ United States ProQR Therapeutics (PRQR) RNA Therapeutics Platform for Rare Disease; Init w/ Buy, TP $32 ? Initiating coverage of ProQR with Buy/High Risk, $32 TP. ProQR is developing RNA-based therapeutics for severe rare diseases lacking approved therapies, with a focus on ophthalmologic disorders. ? Lead program for Leber Congenital Amaurosis 10 (LCA10), a severe eye disease leading to childhood blindness with ~2,000 addressable pts (p.C998X mutation) in US/EU, has achieved proof-of-concept. There are no available therapies for LCA10 and ~1/3 of children have no light perception. ProQR’s drug QR-110 is an intraocular injection that works by correcting a mutation (extra RNA splice site) in the CEP290 gene in a component of our retinas (photoreceptors) critical to vision. ~85% of LCA10 pts have the mutation QR-110 targets. Recent interim Ph1/2 data (Sept. ‘18) have demonstrated very good proof-of-concept in restoring vision to patients who entered the trial with only light perception (stock up ~130% on this). We think the QR-110 data reflected a degree of visual benefit arguably better than what Spark’s Luxturna showed in the related disease LCA2. ProQR will start a Ph2/3 in 1H19 with data 2H20. We assume a ~50% prob. of success (PoS) with peak WW risk-adj. revs of ~$240M. The key competitor is Editas’ gene-editing drug EDIT-101 (IND filed last month). ? Next in the pipeline is Usher Syndrome Type 2A, another disease of blindness with ~14K addressable pts (exon 13 mutations) in US/EU, also with no approved therapies. ProQR’s drug QR-421a is another intra-ocular injection targeting defective photoreceptors. QR-421a works by forcing cells to skip the defect (exon 13) in the USH2A gene that causes the disease. A Ph1/2 trial is expected to start by 4Q18/1Q19 with initial data mid-19. Ahead of the data, we believe that achieving proof-of-concept using a similar delivery approach for LCA10 provides some risk-mitigation. We assume a ~20% PoS with peak WW risk-adj. revs of ~$550M. ? Recently acquired QR-1123 (in-licensed WW rights from Ionis) for autosomal dominant Retinitis Pigmentosa (adRP) with ~6k US/EU addressable pts (P23H mutation). RP typically leads to blindness by middle age, and there are no approved therapies. A Ph1/2 is starting 2019. We assume ~15% PoS with risk- adjusted revs of ~$185M. ProQR Investment Thesis We rate PRQR Buy/High Risk with a $32 target price. ProQR is a Leiden, Netherlands based clinical staged biotechnology company focused on developing novel RNA therapeutics for rare diseases. ProQR expects to advance its lead clinical candidate, QR-110 for Leber Congenital Amaurosis 10 (LCA10), into a Ph2/3 (IILUMINATE) trial in 1H19. Recently reported (September 2018) topline Ph1/2 data for QR-110 in LCA10 demonstrated very good proof-of- concept for vision restoration in a small number of patients. The company expects to advance their second clinical ophthalmology asset QR-421a for Usher Syndrome Type 2A (USH2A) into a Ph1/2 (STELLAR) trial by 4Q18/1Q19. In October 2018, ProQR, in-licensed worldwide rights to QR-1123 (from Ionis Pharmaceuticals) for autosomal dominant retinitis pigmentosa (adRP), which is expected to enter a Ph1/2 clinical trial in 2019. ProQR's dermatologic clinical asset, QR-313 for Dystrophic Epidermolysis Bullosa (DEB), is currently enrolling pts in a Ph1/2 (WINGS) trial with topline data expected in 4Q18/1Q19. Key Aspects of Our Thesis ? Solid rationale for targeting rare ophthalmologic and skin diseases with no approved therapies – LCA10 (a severe eye disease leading to childhood blindness), USH2A (leading cause of combined deafness and blindness), RP (leading to blindness in middle age), and DEB (severe blistering from birth) are diseases with very high unmet needs and no approved therapies. Importantly, the ophthalmological indications are not crowded (although Editas is developing an intravitreal gene editing therapies for LCA10 and USH2A). DEB is more crowded market with several different approaches being taken, but notably none have been successful thus far. ? Good proof-of-concept established in LCA10 – In September 2018, ProQR presented interim data from their Ph1/2 trial. QR-110 treatment resulted in clinically meaningful improvements in two clinical endpoints at three months: best corrected visual acuity (BCVA) and a mobility test. Both of these endpoints could be used as primary endpoints in the pivotal Ph2/3 (ILLUMINATE) trial for LCA10 which ProQR plans on initiating in 1H19, although the trial design has not yet been finalized. ? ProQR has three additional assets in the clinic or entering the clinic within the next year – A Ph1/2 (WINGS) trial for QR-313 in DEB is currently enrolling patients, with initial data expected in 4Q18/1Q19. A Ph1/2 (STELLAR) trial for QR-421a in USH2A is expected to initiate in 4Q18/1Q19. A Ph1/2 for QR-1123 in adRP is expected to initiate in 2019.
RNA Therapeutics – A Novel Class of Drugs Designed to Function At The RNA Level The central dogma of molecular biology states that the flow of genetic information begins with DNA, is transcribed into RNA, and is ultimately translated into proteins that carry out most cellular functions. This provides multiple different points upon which therapeutics could impinge, although to date development efforts have largely focused on drugs designed to function at the protein level. However, recent advances have allowed drug development to shift towards targeting DNA via gene therapy/editing and RNA via splice correction, exon skipping, and mRNA degradation ( Figure 3). ProQR is developing RNA therapies that function by modulating endogenous pre- mRNA transcripts that carry a pathogenic mutation. The therapies are designed to correct extra splice sites introduced by mutations (i.e. splice correction; Figure 4) or to remove entire exons that harbor pathogenic mutations (i.e. exon skipping; Figure 5). Through these mechanisms, ProQR's therapies are designed to produce a corrected mRNA transcript that can be translated into an operational (although smaller in the case of exon skipping) protein that is able to function normally. In contrast, other types of antisense oligonucleotides and RNAi function by mediating mRNA degradation through the recruitment of endogenous protein machinery (RNase H and RISC, respectively). ProQR's RNA therapies are also differentiated from mRNA therapies, which function by delivering an exogenous in vitro transcribed mRNA into target cells, rather than corrected the mutated endogenous pre-mRNA. ProQR's lead clinical candidate, QR-110, is designed to function through a splice correction mechanism for patients with LCA10 that harbor the Cys998X mutation ( Figure 4). The Cys998X mutation results in an aberrant (i.e. extra) splice site prior to exon 27 in the CEP290 gene, which results in the inclusion of a pseudo-exon in the CEP290 mRNA. Unfortunately, the pseudo-exon carries a stop codon, which results in the premature truncation and loss-of-function of the CEP290 protein. Treatment with QR-110 is able to block the aberrant splice site, which results in the correct removal of the pseudo-exon and allows the translation of a full-length, function CEP290 protein. ProQR's QR-421a and QR-313, both antisense oligonucleotides, are designed to function through an exon skipping mechanism for patients with USH2A who harbor a mutation in exon 13 in the USH2A gene and patients with DEB that harbor a mutation in exon 73 of the COL7A1 gene, respectively ( Figure 5). Both drugs block splicing factors, which results in the removal of the exon carrying the pathogenic mutations. ProQR’s QR-1123, licensed from Ionis Pharmaceuticals, is a gapmer (a type of oligonucleotide) with an allele–specific knockdown mechanism. This means that QR-1123 specifically knocks-down the mutant allele (in this case a P23H mutation in the RHO gene causing adRP) while sparing the wild-type allele. ProQR has also developed an RNA editing platform called Axiomer. The technology functions by having a specially designed RNA editing oligonucleotide bind to a target RNA, which then recruits a protein called ADAR (adenosine deaminase acting on RNA). ADAR then facilitates an A-to-G conversion at the target location. Given that there are more than ~20,000 disease caused by G-to-A mutations, this platform has the potential to become a useful therapeutic approach. While none of ProQR's lead assets were developed utilizing the Axiomer platform, ProQR has partnered with Galapagos to work on targets in fibrosis using this technology.
RNA Therapeutics Have Several Benefits Over Gene Therapy Genetic diseases caused by mutations in a single gene that result in loss-of-function recessive phenotypes (such as LCA10, recessive DEB, and USH2A), are often good candidates for gene therapy. However, an RNA therapy approach provides several benefits over gene therapy, including: 1. Not limited by the size of the gene being targeted – Gene therapy is currently limited by the size of the gene product that can be delivered. For example, some genes (such as CEP290, which harbors mutations that cause LCA10) are too large to be enclosed within currently used viral vectors. In contrast, RNA therapy does not require the delivery of an exogenous genomic sequence, and therefore is into limited by the size of the target mRNA. 2. Unlikely to result in target protein overexpression – RNA therapies function by repairing endogenously expressed RNA transcripts. Even if the therapy were 100% efficient, it is unlikely to result in target protein expression greater than physiological levels. On the other hand, gene therapy introduces an exogenous DNA sequence which runs the risk of inducing target protein expression at levels higher than normal. This risk becomes especially important when considering proteins associated with cellular toxicity when overexpressed. 3. Lower risk of permanent off-target effects – RNA therapies require patients to be dosed repeatedly in order to maintain a therapeutic benefit. Therefore, RNA treatment can be halted if complications arise, which could potentially allow for a reversal of adverse effects. In contrast, the goal of gene therapy is a permanent genetic change after a single administration, which carries the potential for not only harmful on-target effects, but also potentially serious off- target effects that cannot be reversed. Leber Congenital Amaurosis Leber Congenital Amaurosis (LCA) is a genetic disease characterized by progressive vision loss typically beginning early in life. Vision loss is mediated by a disruption of a process called phototransduction, which occurs in specialized retinal cells called photoreceptors. For most types of LCA, both types of photoreceptors, rods (responsible for low-light & black-and-white vision) and cones (responsible for color perception) are affected, which results in progressive blindness. The prevalence of LCA is estimated to be about 1 in 60,000 worldwide. Leber Congenital Amaurosis 10 There are at least 16 different subtypes of LCA. One of the most common is LCA10, which is caused by autosomal recessive loss-of-function mutations in the CEP290 gene. This protein plays a role in cilium function (cilia are cellular organelles that protrude outside of the cell and play an important role interacting with the extracellular environment), which is particularly important for photoreceptor cell function. LCA10 is considered one of the more severe forms of LCA and is generally characterized by preserved cone vision and severely impaired rod vision (although both types of photoreceptor cells are affected at later stages of the disease). This subtype is estimated to affect about 15-20% of LCA patients ( Figure 6). Diagnosis and Management of LCA10 LCA10 diagnosis can typically be made on clinical examination: patients first present by failing a vision screening test at an early age, with additional symptoms such as eye rubbing and involuntary eye movements providing diagnostic clues. While an LCA10 diagnosis is confirmable through genetic testing, not all patients are provided this option given the lack of disease modifying therapies available for treatment. In other words, there has historically been no benefit for clinicians or insurance companies knowing a patient's specific genotype. Importantly, there has been a recent push for LCA genotyping since the approval of Luxturna (gene therapy; Spark Therapeutics) for LCA2, as well as the increased interest in development of therapies for other LCA subtypes, such as QR-110 (ProQR's lead clinical candidate) and EDIT-101 (gene therapy in preclinical development; Editas) for LCA10. Currently, there are no approved therapies for LCA10. Most patients receive only supportive care, which is primarily focused on visual aids such as glasses and magnifying glasses. Unfortunately, many of these patients are unable to work and maintain careers given their profound loss of vision. QR-110 Is Being Developed for Most Common LCA10 Mutation ProQR is developing their lead therapeutic, QR-110, for the treatment of LCA10. QR-110 is designed to target a specific mutation in CEP290 : p.Cys998X (meaning the insertion of a premature stop codon at position 998). This mutation results from the genetic change c.2991+1655A>G (meaning that an A was changed to a G at 1655bp from the 5 ’ end of the intron immediately downstream of the CEP290 exon ending at position 2991). This genetic change creates a novel cryptic splice site – a splice site which is not normally present – that gives rise to a truncated protein that is not functional. While minimal amounts of wild-type protein (i.e. functional) are still occasionally produced in some patients, it is often not sufficient to compensate for the loss-of-function resulting from the truncated protein. QR-110 is designed to "mask" this cryptic splice site, thereby preventing truncation of the CEP290 protein and shifting the ratio of mutant to wild-type transcript in favor of the wild-type transcript. Although there have been a number of other CEP290 mutations that have been implicated in LCA10, Cys998X is the most common. ~2,000 LCA10 Patients Could Benefit from QR- 110 QR-110 is designed to only treat LCA10 patients carrying a p.Cys998X mutation. The p.Cys998X mutation is relatively common with about 85% of LCA10 patients carrying at least one allele (~10-20% of these patients are homozygotes and = 75% are heterozygotes). We estimate the addressable market for QR-110 is about 2,000 LCA10 Cys998X patients in the Western World (US and EU). Preclinical Data Demonstrates QR-110 Can Modulate CEP290 Cys998X Mutations ProQR has shown that QR-110 corrects disease-causing RNA in patient cells in- vitro , resulting in increased CEP290 protein levels and improvements in cilia function. In-vivo , the company has shown that QR-110 makes it to the outer nuclear layer which houses the photoreceptor cells underlying LCA10 pathophysiology. QR-110 In-Vitro Proof-of-Concept Demonstrates Molecular Mechanism Is Working In patient-derived fibroblasts, ProQR has shown that treatment with QR-110 (25 µM) is sufficient to correct CEP290 transcripts and increase CEP290 protein levels
This provides evidence that the QR-110 is working as expected and is converting mutant transcripts into wild-type (i.e. functional) transcripts. However, this model has its limitations given that fibroblast cells, even though they carry disease-causing patient mutations, are not directly linked to LCA10 disease progression ProQR has used an optic cup model in which patient-derived fibroblasts are reprogrammed to iPS cells, which are then differentiated to retinal pigmented epithelium cells and neural retinal cells. This organoid model is highly relevant since it contains not only patient-derived mutations, but also utilizes cells resembling those involved in LCA10. Using this model, ProQR has demonstrated that treatment with QR-110 (10 µM) is sufficient to significantly increase CEP290 wild-type transcript levels and decrease CEP290 mutant transcript levels ( Figure 7, right panel). Furthermore, there an improvement in cilium function was observed, as indicated by an increase in the percentage of ciliated cells and the length of cilia, which suggests the drug is exerting an on-target effect. etc. etc. het is een wat te lijvig rapport om helemaal hier neer te zetten..zal kijken of ik iets van highlights tegenkom.
Prevalence of Patients Who Might Benefit from QR-313 The subset of DEB patients who have mutations in exon 73 is about 15%. We calculate an addressable patient population of about 400 patients in the Western World. QR-313 Preclinical Data Is Positive In patient-derived fibroblasts, ProQR has shown that treatment with QR-313 (100 µM) is sufficient to increase COL7A1 protein levels ( Figure 16, left panel). These cells carry disease-causing patient mutations making them a relevant model. This work is an important proof-of-concept demonstrating that QR-313 is having the desired molecular effect. QR-313 is formulated as a topical cream which will be applied to patient skin wounds. ProQR has demonstrated that QR-313 reaches the relevant cells of the epidermis and dermis in a minipig wounded skin model ( Figure 16, right panel). In contrast, QR-313 does not penetrate intact skin. Upcoming Milestones for QR-313 The upcoming milestones for QR-313 in DEB with mutations in exon 73 are: 1) interim data from Phase 1/2 (WINGS; NCT03605069) in 4Q18/1Q19 and 2) complete readout of the trial in 2019. Competition in DEB A number of different companies are working on DEB, taking approaches such as topical peptides, gene therapy, and autologous cell therapy combined with gene therapy. In 2017, Amicus Therapeutics stopped development of SD-101, an anti- inflammatory for EB, when it failed to meet primary and secondary endpoints in a Ph3 trial. Probability of Success We model QR-110 with a 50% probability of success (PoS), QR-421a with a 20% PoS, QR-1123 with a 15% PoS, and QR-313 with a 15% PoS. We assign a 50% PoS for QR-110 given the recent positive Ph1/2 proof-of-concept data. We assign a slightly higher PoS for QR-421a in USH2A based on the positive read-through from clinical data in LCA10. A recent publication that analyzed over 400K clinical trials found the probability of a Ph1 asset gaining regulatory approval was 13.8%. 1 Based on this we assign a 15% PoS for QR-313 and QR-1123. Our bull case assumes an 80% PoS for QR-110 in LCA10, a 30% PoS for QR-421a in USH2A, and a 25% PoS for QR-313 in DEB. Our bear case assumes ProQR trades at cash. Assumptions for QR-110 in LCA10 We assume QR-110 will be approved for use in LCA10. We estimate a peak addressable population of 900/1,300 in the US/EU in 2032. We assume a peak market share of 60%/50% in 2032, which implies a peak population of LCA10 patients treated with QR-110 of 460/540 in the US/EU. etc. etc. uiteraard met bijbehorende disclaimers, grafieken, cijfers, modellen, foto´s etc.
Beste Flosz,, dank voor dit bericht, leuke herinneringen aan datgene wat je altijd plaatste bij Crucell.
AB, maar heb ik ooit wat gehad aan Kempen?
ProQR Therapeutics Enters Oversold Territory Zacks Zacks Equity Research ,Zacks•October 1, 2019 ProQR Therapeutics Enters Oversold Territory More ProQR Therapeutics N.V. PRQR has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at PRQR given that, according to its RSI reading of 22.62, it is now in oversold territory. What is RSI? RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present. Other Factors Yet, PRQR’s low RSI value isn’t the only reason to have some optimism over a coming turnaround, as there has been plenty of positive earnings estimate revision activity as of late. This is especially true when investors take a deep dive into some of these estimate revision stats and recent changes to ProQR Therapeutics’ earnings consensus. Over the past two months, investors have seen 2 earnings estimate revision move higher, compared with none lower, at least when looking at the key current year time frame. And the consensus estimate for PRQR has also been on an upward trend over the past 60 days, as estimates have risen 9.7% over the last two months. If this wasn’t enough, ProQR Therapeutics also has a Zacks Rank #1 (Strong Buy) which puts it into rare company among its peers. So, given all of these factors, investors may want to consider getting in on this stock now (or holding on), as there are some favorable trends that could bubble up for this stock before long. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Free: Zacks’ Single Best Stock Set to Double Today you are invited to download our just-released Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all. This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain. Download Free Report Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ProQR Therapeutics N.V. (PRQR) : Free Stock Analysis Reportfinance.yahoo.com/news/proqr-present-...
ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019 • Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10 • Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020 • QR-1123 Investigational New Drug application active for autosomal dominant retinitis pigmentosa • €49.3 million net proceeds from public offering extends cash runway into 2022 LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced results for the third quarter of 2019. “During the third quarter we made great progress towards our mission to bring novel RNA therapies to patients and we recently strengthened our capital position,” said Daniel A. de Boer, chief executive officer of ProQR. “In October we announced that LCA10 patients experienced a significant improvement in vision after treatment with sepofarsen in a Phase 1/2 trial. These results strengthen our confidence in the design of the ongoing pivotal Illuminate Phase 2/3 trial and our broader inherited retinal diseases pipeline. The Phase 1/2 trial of QR-421a in Usher syndrome is on track to deliver first clinical data in Q1 2020 and we are about to dose a first patient in a Phase 1/2 trial of QR-1123 for adRP. We strengthened our financial position with a public offering in October that will allow us to fund operations into 2022, well beyond the expected top-line readout of Illuminate.” Corporate Highlights and Business Update Sepofarsen (QR-110) for Leber’s congenital amaurosis 10 (LCA10) • Presented positive top-line results from the Phase 1/2 clinical trial. In the trial, sepofarsen was observed to be well tolerated with rapid, significant and durable improvements in vision observed at month twelve. The target registration dose for the ongoing Phase 2/3 Illuminate trial showed a favorable benefit/risk profile in the Phase 1/2 trial. • The top-line results from the Phase 1/2 trial support confidence in the design of the ongoing Phase 2/3 Illuminate trial that could be the sole registration trial for the program. Top-line data from Illuminate are expected during the first half of 2021. • Received Rare Pediatric Disease designation from the Food and Drug Administration (FDA) for the treatment of LCA10. QR-421a for Usher syndrome type 2 • The Phase 1/2 Stellar trial of QR-421a in patients with Usher syndrome type 2 is ongoing and on track to deliver interim data during the first quarter of 2020. QR-1123 for autosomal dominant retinitis pigmentosa (adRP) • The FDA cleared the Investigational New Drug (IND) application to start a first-in-human clinical trial in patients with adRP. ProQR plans to start enrolling patients in the Phase 1/2 Aurora trial in 2019. • Received Fast Track designation from the FDA. Business Updates • Closed an underwritten public offering of 9,090,909 ordinary shares on October 18, 2019 at a price of $5.50 per share with full exercise of underwriters’ option to purchase 1,363,636 additional ordinary shares. Net proceeds totaled approximately €49.3 million. With the addition of this capital ProQR’s operations are funded into 2022.
Financial Highlights At September 30, 2019, prior to the offering on October 18th, ProQR held cash and cash equivalents of €74.8 million, compared to €105.6 million at December 31, 2018. The cash balance at September 30, 2019 excludes the net proceeds of €49.3 million from the underwritten offering of ordinary shares in October 2019. Net cash used in operating activities during the three-month period ended September 30, 2019 was €8.8 million, compared to €4.3 million for the same period last year. Research and development costs increased to €11.1 million for the quarter ended September 30, 2019 compared to €6.3 million for the same period last year due to increased clinical trial activity. General and administrative costs increased to €2.9 million for the quarter ended September 30, 2019 compared to €2.6 million for the same period last year. Net loss for the three-month period ended September 30, 2019 was €12.2 million or €0.31 per share, compared to a €6.0 million loss or €0.18 per share for the same period last year. In October 2019 the Company sold an aggregate of 10.5 million ordinary shares, with net proceeds to the Company of €49.3 million. For further financial information for the period ended September 30, 2019, please refer to the financial statements appearing at the end of this release. About Sepofarsen Sepofarsen (QR-110) is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of Leber’s congenital amaurosis 10 due to the p.Cys998X mutation (also known as the c.2991+1655A>G mutation) in the CEP290 gene. The p.Cys998X mutation leads to aberrant splicing of the mRNA and non-functional CEP290 protein. Sepofarsen is designed to enable normal splicing, resulting in restoration of normal (wild type) CEP290 mRNA and subsequent production of functional CEP290 protein. Sepofarsen is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the United States and the European Union and received fast-track designation and rare pediatric disease designation from the FDA as well as access to the PRIME scheme by the EMA. About QR-421a QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of vision loss in Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. QR-421a is designed to restore functional Usherin protein by using an exon skipping approach with the aim to stop or reverse vision loss in patients. QR-421a is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the United States and the European Union and received fast-track designation from the FDA. About QR-1123 QR-1123 is a first-in-class investigational RNA-based oligonucleotide that was discovered and developed by Ionis Pharmaceuticals using Ionis’ proprietary antisense technology for the treatment of adRP due to the P23H mutation in the RHO gene. The therapy aims to inhibit the formation of the mutated toxic version of the rhodopsin protein by specifically binding the mutated RHO mRNA. Binding of QR-1123 causes allele specific knockdown of the mutant mRNA by a mechanism called RNase H mediated cleavage without affecting the normal RHO mRNA. QR-1123 is intended to be administered through intravitreal injections in the eye and received IND clearance in August 2019. About ProQR ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as Leber’s congenital amaurosis 10, Usher syndrome and autosomal dominant retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. *Since 2012* FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding sepofarsen (QR-110) and the clinical development and the therapeutic potential thereof, statements regarding our pipeline of programs targeting inherited retinal dystrophies, statements regarding QR-421a, and the clinical development and the therapeutic potential thereof, statements regarding QR-1123 and the clinical development and therapeutic potential thereof, and our financial position and cash runway. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
De tabellen met het financiele overzicht krijg ik hier niet leesbaar gekopieerd, sorry.
Belangrijk gegeven is denk ik: "Research and development costs increased to €11.1 million for the quarter ended September 30, 2019 compared to €6.3 million for the same period last year due to increased clinical trial activity." Dat belooft veel binnenkort.
Voor mij is het belangrijkste dat ze op schema zitten met de Usher trial. Elk mogelijk negatief geluid terzake had een kleine ramp voor de koers kunnen betekenen.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee